Long-term use of thiazolidinediones and fractures in type 2 diabetes: A meta-analysis

CMAJ. Canadian Medical Association Journal

Volumn 180, Issue 1, 2009, Pages 32-39

  Loke, Yoon K ^a   Singh, Sonal ^b   Furberg, Curt D ^b  

^a UNIVERSITY OF EAST ANGLIA   (United Kingdom)

^b WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

METFORMIN; PIOGLITAZONE; ROSIGLITAZONE; SULFONYLUREA; TROGLITAZONE; 2,4 THIAZOLIDINEDIONE DERIVATIVE; ANTIDIABETIC AGENT;

ARTICLE; BONE DENSITY; CLINICAL TRIAL; CONFIDENCE INTERVAL; FRACTURE; HIP; HUMAN; LUMBAR SPINE; META ANALYSIS; NON INSULIN DEPENDENT DIABETES MELLITUS; OSTEOLYSIS; RISK ASSESSMENT; SENSITIVITY ANALYSIS; SIDE EFFECT; SYSTEMATIC REVIEW; CHEMICALLY INDUCED DISORDER; DRUG EFFECT; FEMALE; MALE; TREATMENT OUTCOME;

BONE DENSITY; DIABETES MELLITUS, TYPE 2; FEMALE; FRACTURES, BONE; HUMANS; HYPOGLYCEMIC AGENTS; MALE; THIAZOLIDINEDIONES; TREATMENT OUTCOME;

EID: 58849094131     PISSN: 08203946     EISSN: 14882329     Source Type: Journal    
DOI: 10.1503/cmaj.080486     Document Type: Article

References (60)

1. Singh S, Loke YK, Furberg CD. Long-term risk of cardiovascular events with rosiglitazone: a meta-analysis. JAMA 2007;298:1189-95.
2. Singh S, Loke YK, Furberg CD. Thiazolidinediones and heart failure: a teleoanalysis. Diabetes Care 2007;30:2148-53.
3. Lincoff AM, Wolski K, Nicholls SJ, et al. Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials. JAMA 2007;298:1180-8.
4. Lago RM, Singh PP, Nesto RW. Congestive heart failure and cardiovascular death in patients with prediabetes and type 2 diabetes given thiazolidinediones: a meta-analysis of randomised clinical trials. Lancet 2007;370:1129-36.
5. Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 2007;356:2457-71.
6. Kahn SE, Haffner SM, Heise MA, et al.; ADOPT Study Group. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy [erratum in N Engl J Med 2007; 356:1387-8]. N Engl J Med 2006;355:2427-43.
7. Clinical trial observation of an increased incidence of fractures in female patients who received long-term treatment with Avandia® (rosiglitazone maleate) tablets for type 2 diabetes mellitus [Dear Health Care Provider letter]. Philadelphia (PA): GlaxoSmithKline; 2007. Available: www.fda.gov/medwatch/safety/2007/Avandia-GSK-Ltr.pdf (accessed 2008 Jul 13).
8. Observation of an increased incidence of fractures in female patients who received long-term treatment with ACTOS (pioglitazone hydrochloride) tablets for type 2 diabetes mellitus [Dear Health Care Provider letter]. Deerfield (IL): Takeda Pharmaceuticals North America; 2007. Available: www.fda.gov/MEDWATCH/ SAFETY/2007/Actosmar0807.pdf (accessed 2008 Jul 13).
9. Increased incidence of fractures in female patients who received long-term treatment with ACTOS (pioglitazone hydrochloride) tablets for type 2 diabetes mellitus. Toronto (ON): Eli Lily Canada Inc.; 2007. Available: www.hc-sc.gc.ca/dhp-mps/medeff/advisories-avis/prof/2007/actos-hpc-cps-2-e.html (accessed 2008 Jul 13).
10. Bonds DE, Larson JC, Schwartz AV, et al. Risk of fracture in women with type 2 diabetes: the Women's Health Initiative Observational Study. J Clin Endocrinol Metab 2006;91:3404-10.
11. Janghorbani M, Van Dam RM, Willett WC, et al. Systematic review of type 1 and type 2 diabetes mellitus and risk of fracture. Am J Epidemiol 2007;166:495-505.
12. GlaxoSmithKline clinical trial register. Brentford (UK): GlaxoSmithKline; 2008. Available: http://ctr.gsk.co.uk/welcome.asp (accessed 2008 Sept 10).
13. Clinical study report summaries. Osaka (Japan): Takeda Pharmaceuticals Company Limited; 2008. Available: www.takeda.com/c-t/report-summaries/article- 53.html (accessed 2008 Jul 13).
14. Clinical Study Results database. Available: www.clinicalstudyresults.org (accessed 2008 Jul 13).
15. Loke YK, Price D, Herxheimer A. Adverse effects. In: Higgins JPT, Green S, editors. Cochrane handbook for systematic reviews of interventions version 5.0.0 [updated February 2008]. Chichester (UK): The Cochrane Collaboration; 2008. Available: www.cochrane-handbook.org (accessed 2008 Sept 11).
16. Bradburn MJ, Deeks JJ, Berlin JA, et al. Much ado about nothing: a comparison of the performance of meta-analytical methods with rare events. Stat Med 2007;26:53-77.
17. Higgins JP, Thompson SG, Deeks JJ, et al. Measuring inconsistency in metaanalyses. BMJ 2003;327:557-60.
18. Ioannidis JP, Patsopoulos NA, Evangelou E. Uncertainty in heterogeneity estimates in meta-analyses. BMJ 2007;335:914-6.
19. Rosenberg MS. The file-drawer problem revisited: a general weighted method for calculating fail-safe numbers in meta-analysis. Evolution 2005;59:464-8.
20. Cates CJ. Simpson's paradox and calculation of number needed to treat from meta-analysis. BMC Med Res Methodol 2002;2:1.
21. Schünemann HJ, Oxman AD, Vist GE, et al. Interpreting results and drawing conclusions. In: Higgins JPT, Green S, editors. Cochrane handbook for systematic reviews of interventions version 5.0.0 [updated February 2008]. Chichester (UK): The Cochrane Collaboration; 2008. Available: www.cochrane-handbook.org (accessed 2008 Sept 11).
22. Smeeth L, Haines A, Ebrahim S. Numbers needed to treat derived from meta-analyses - sometimes informative, usually misleading. BMJ 1999;318:1548-51.
23. Kahn SE, Zinman B, Lachin JM, et al.; ADOPT Study Group. Rosiglitazone Associated fractures in type 2 diabetes: an analysis from ADOPT. Diabetes Care 2008;31:845-51.
24. Dormandy JA, Charbonnel B, Eckland DJ, et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive study (PROspective pioglitazone clinical trial in macrovascular events): a randomised controlled trial. Lancet 2005;366:1279-89.
25. Actos prescribing information. Deerfield (Illinois): Takeda Pharmaceuticals America Inc.; 2007. Available: www.actos.com/actos/ prescribinginfo.aspx (accessed 2008 Jul 13).
26. A randomised, multi-centre, phase IV, double-blind, parallel group study comparing the effects of 52 weeks' administration of AVANDAMET and metformin plus sulphonylurea on change in HbA1c from baseline in overweight type 2 diabetics poorly controlled on metformin [study no AVM100264]. Brentford (UK): Glaxo-SmithKline; 2008. Available: http://ctr.gsk.co.uk/Summary/rosiglitazone/ studylist.asp (accessed 2008 Jul 13).
27. RAS Rosiglitazone and Atherosclerosis Study: a 1 year randomised, double-blind, parallel group, placebo controlled study to evaluate the efficacy of rosiglitazone on the progression of intima-media thickness in the carotid artery in subjects with insulin resistance syndrome and/or type 2 diabetes mellitus [study no 049653/334]. Brentford (UK): GlaxoSmithKline; 2008. Available: http://ctr.gsk.co.uk/Summary/rosiglitazone/studylist.asp (accessed 2008 Jul 13).
28. Rosiglitazone and Plaque Study: a 12 month randomised, double-blind, placebo-controlled, magnetic resonance imaging study to evaluate the effect of rosiglitazone on the structure and composition of carotid atherosclerotic plaques in subjects with type 2 diabetes mellitus and coexisting vascular disease or hypertension [study no 049653/351]. Brentford (UK): GlaxoSmithKline; 2008. Available: http://ctr.gsk.co.uk/Summary/rosiglitazone/studylist.asp (accessed 2008 Jul 13).
29. Jain R, Osei K, Kupfer S, et al. Long-term safety of pioglitazone versus glyburide in patients with recently diagnosed type 2 diabetes mellitus study no 049653/351. Pharmacotherapy 2006;26:1388-95.
30. Nissen SE, Nicholls SJ, Wolski K, et al. PERISCOPE Investigators. Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes: the PERISCOPE randomized controlled trial. JAMA 2008;299:1561-73.
31. DeFronzo RA. Actos Now for Prevention of Diabetes (ACT NOW). NCT00220961. Proceedings of the American Diabetes Association 68th Scientific Sessions: Late Breaking Clinical Studies. 2008 Jun 6-10; San Fransisco. Alexandria (VA) : The American Diabetes Association; 2008.
32. Seufert J, Urquhart R. 2-year effects of pioglitazone add-on to sulfonylurea or metformin on oral glucose tolerance in patients with type 2 diabetes. Diabetes Res Clin Pract 2008;79:453-60.
33. Meier C, Kraenzlin ME, Bodmer M, et al. Use of thiazolidinediones and fracture risk. Arch Intern Med 2008;168:820-5.
34. Fracture diagnoses in patients receiving monotherapy with antidiabetic agents, including hand and foot fractures [study no WEUSRTP2181]. Brentford (UK): GlaxoSmithKline; 2008. Available: http://ctr.gsk.co.uk/Summary/ rosiglitazone/studylist.asp (accessed 2008 Jul 13).
35. Grey A, Bolland M, Gamble G, et al. The peroxisome proliferator-activated receptor-{gamma} agonist rosiglitazone decreases bone formation and bone mineral density in healthy postmenopausal women: a randomized, controlled trial. J Clin Endocrinol Metab 2007;92:1305-10.
36. Glintborg D, Andersen M, Hagen C, et al. Association of pioglitazone treatment with decreased bone mineral density in obese premenopausal patients with polycystic ovary syndrome: a randomized, placebo-controlled trial. J Clin Endocrinol Metab 2008;93:1696-701.
37. Yaturu S, Bryant B, Jain SK. Thiazolidinedione treatment decreases bone mineral density in type 2 diabetic men. Diabetes Care 2007;30:1574-6.
38. Schwartz AV, Sellmeyer DE, Vittinghoff E, et al. Thiazolidinedione use and bone loss in older diabetic adults. J Clin Endocrinol Metab 2006;91:3349-5.
39. Cook RJ, Sackett DL. The number needed to treat: a clinically useful measure of treatment effect. BMJ 1995;310:452-4.
40. Schwartz AV, Sellmeyer DE, Ensrud KE, et al. Older women with diabetes have an increased risk of fractures. A prospective study. J Clin Endocrinol Metab 2001;86:32-8.
41. Berberoglu Z, Gursoy A, Bayraktar N, et al. Rosiglitazone decreases serum bone-specific alkaline phosphatase activity in postmenopausal diabetic women. J Clin Endocrinol Metab 2007;92:3523-30.
42. Ali AA, Weinstein RS, Stewart SA, et al. Rosiglitazone causes bone loss in mice by suppressing osteoblast differentiation and bone formation. Endocrinology 2005;146:1226-35.
43. Rzonca SO, Suva LJ, Gaddy D, et al. Bone is a target for the antidiabetic compound rosiglitazone. Endocrinology 2004;145:401-6.
44. Soroceanu MA, Miao D, Bai XY, et al. Rosiglitazone impacts negatively on bone by promoting osteoblast/osteocyte apoptosis. J Endocrinol 2004;183:203-16.
45. Wan Y, Chong LW, Evans RM. PPAR-gamma regulates osteoclastogenesis in mice. Nat Med 2007;13:1496-503.
46. Dagdelen S, Sener D, Bayraktar M. Influence of type 2 diabetes mellitus on bone mineral density response to bisphosphonates in late postmenopausal osteoporosis. Adv Ther 2007;24:1314-20.
47. Sottile V, Seuwen K, Kneissel M. Enhanced marrow adipogenesis and bone resorption in estrogen-deprived rats treated with the PPAR agonist BRL49653 (rosiglitazone). Calcif Tissue Int 2004;75:329-37.
48. Schwartz AV, Cummings SR. Does rosiglitazone adversely affect bone formation and bone mineral density in postmenopausal women? Nat Clin Pract Endocrinol Metab 2007;3:622-3.
49. Sanders KM, Seeman E, Ugoni AM, et al. Age- and gender-specific rate of fractures in Australia: a population-based study. Osteoporos Int 1999;10:240-7.
50. Worthy K, Feight A. One year post-pediatric exclusivity post-marketing adverse event review: drug use data Avandia (rosiglitazone) tablet: NDA 21-071PID # 040849 [memorandum]. Rockville (MD): Department of Health and Human Services, US Food and Drug Administration, Public Health Service, Center for Drug Evaluation and Research; 2006. Available: www.fda.gov/ohrms/dockets/ac/06/ briefing/2006-4254b-05-02-RosiglitazoneUseData%20Cleared.pdf (accessed 2008 Jul 13).
51. Monami M, Cresci B, Colombini A, et al. Bone fractures and hypoglycemic treatment in type 2 diabetic patients: a case-control study. Diabetes Care 2008;31:199-203.
52. Forsen L, Meyer HE, Midthjell K, et al. Diabetes mellitus and the incidence of hip fracture: results from the Nord-Trondelag Health Survey. Diabetologia 1999;42:920-5.
53. Nicodemus KK, Folsom AR. Type 1 and type 2 diabetes and incident hip fractures in postmenopausal women. Diabetes Care 2001;24:1192-7.
54. Loke YK, Price D, Derry S, et al. Case reports of suspected adverse drug reactions - systematic literature survey of follow-up. BMJ 2006;332:335-9.
55. US Food and Drug Administration. Adverse event reporting system. Rockville (MD): The Administration; 2008. Available: www.fda.gov/cder/aers/ default.htm (accessed 2008 Jul 13).
56. Canadian Adverse Drug Reaction Monitoring Program (CADRMP) adverse reaction database. Ottawa (ON): Health Canada; 2006. Available: www.hc-sc.gc.ca/dhp-mps/medeff/databasdon/index-eng.php (accessed 2008 Jul 13).
57. Quesada-Gomez JM, Serrano-Alferez I. Nonhypoglycemic effects of thiazolidinediones. Ann Intern Med 2001;135:1007-8.
58. Richter B, Bandeira-Echtler E, Bergerhoff K, et al. Pioglitazone for type 2 diabetes mellitus. Cochrane Database Syst Rev 2006;4:CD006060.
59. Richter B, Bandeira-Echtler E, Bergerhoff K, et al. Rosiglitazone for type 2 diabetes mellitus [review]. Cochrane Database Syst Rev 2007;3:CD006063.
60. National Institute for Health and Clinical Excellence. GC66 diabetes - type 2 update: NICE guidelines. London (UK): The Institute; 2008. Available: www.nice.org.uk/Guidance/CG66/NiceGuidance/pdf/English (accessed 2008 Jul 13).